Skip to main content
. 2014 Jun 11;3:293. doi: 10.1186/2193-1801-3-293

Figure 2.

Figure 2

Response of GT-based combination therapy versus non GT-based combination for metastatic breast cancer. ORR were analyzed with the fixed effect model. (A: Meta-analysis of ORR, subgroup: gemcitabine role; B: Meta-analysis of ORR, subgroup: therapy lines).